Publications
Original Article
A plasma protein derived TGFβ signature is a prognostic indicator in triple negative breast cancer
General Immune Research
2019
Authors:
Katayama H, Tsou P, Kobayashi M, Capello M, Wang H, Esteva F, Disis ML, Hanash S.
Journal:
NPJ Precision Oncology
Volume:
3
Page:
10
Review Article
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
2019
Authors:
Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.
Journal:
Journal of Immunotherapy Cancer
Volume:
7(1)
Page:
131
Review Article
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer
General Immune Research
2019
Authors:
Page DB, Bear H, Prabhakaran S, Gatti-Mays ME, Thomas A, Cobain E, McArthur H, Balko JM, Gameiro SR, Nanda R, Gulley JL, Kalinsky K, White J, Litton J, Chmura SJ, Polley MY, Vincent B, Cescon DW, Disis ML, Sparano JA, Mittendorf EA, Adams S.
Journal:
NPJ Breast Cancer
Volume:
5
Page:
34
Review Article
Crafting a JAMA Oncology Clinical Challenge
2019
Authors:
Morrow M, Disis ML.
Journal:
JAMA Oncology
Volume:
Page:
Review Article
Immuno-Oncology in the Era of Personalized Medicine
2019
Authors:
Gwin WR 3rd, Disis ML, Ruiz-Garcia E.
Journal:
Advances of Experimental Medicine and Biology
Volume:
1168
Page:
117-129
Review Article
Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
2019
Authors:
Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.
Journal:
Journal of Immunotherapy Cancer
Volume:
7(1)
Page:
167
Review Article
Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
2019
Authors:
Pal SK, Miller MJ, Agarwal N, Chang SM, Chavez-MacGregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-Galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE.
Journal:
Journal of Clinical Oncology
Volume:
37(10)
Page:
834-849
Original Article
Tumor-associated antigens identified early in mouse mammary tumor development can be effective vaccine targets
Cancer Vaccines
2019
Authors:
Stanton SE, Gad E, Corulli LR, Lu H, Disis ML.
Journal:
Vaccine
Volume:
37(27)
Page:
3552-3561
Review Article
Current Landscape of Immunotherapy in Breast Cancer: A Review
2019
Authors:
Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, Bear H, McArthur HL, Frank E, Perlmutter J, Page DB, Vincent B, Hayes JF, Gulley JL, Litton JK, Hortobagyi GN, Chia S, Krop I, White J, Sparano J, Disis ML, Mittendorf EA.
Journal:
JAMA Oncology
Volume:
5(8)
Page:
1205-1214
Original Article
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial
Clinical Trials
2019
Authors:
Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, Hamilton EP, Annunziata CM, Grote HJ, von Heydebreck A, Grewal J, Chand V, Gulley JL.
Journal:
Jama Oncology
Volume:
5(3)
Page:
393-401
